Navigation Links
PBX1 identified as a new pioneer factor underlying progression in breast cancer
Date:11/17/2011

The presence of a new pioneer factor, known as PBX1, can guide the response to estrogen in breast cancer cells according to researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center in results published on November 17 in the open-access journal PLoS Genetics. This research reveals that PBX1 alone can determine the risk of the spread of cancer in patients with estrogen receptor alpha (ERα)-positive breast cancer, which accounts for about two-thirds of all breast cancers diagnosed in North America.

Pioneer factors are an emerging class of chromatin remodelers with the capacity to modulate cellular identity as they set the stage by defining the genomic regions accessible for transcription factors. "Since cancer is characterized by a loss of cell-fate identity, it is not surprising that other pioneer factors have already been characterized as oncogenic factors in breast cancer, but PBX1 is one that discriminates progression," said Dr. Mathieu Lupien, assistant professor of genetics, Norris Cotton Cancer Center, Dartmouth Medical School, who served as principal investigator for the study. Specifically, this research demonstrates that PBX1 directly modulates chromatin compaction at discrete genomic regions to promote the recruitment of the transcription factor ERα, driving the proliferative response to estrogen in breast cancer cells.

"Unfortunately, numerous ERα-positive patients with breast cancer progress to more advanced stages of the disease as they develop resistance to endocrine therapies, which directly target ERα." said lead author Dr. Luca Magnani, post-doctoral scientist.

"This work may rapidly translate to the clinic because PBX1 could likely serve as a prognostic marker for ERα-positive breast cancer progression. It also highlights the potential therapeutic benefit of developing means to antagonize pioneer factors such as PBX1 to prevent breast cancer progression" said Dr. Lupien.


'/>"/>

Contact: Dr. Mathieu Lupien
Mathieu.Lupien@Dartmouth.edu
603-653-9041
Public Library of Science
Source:Eurekalert

Related medicine news :

1. Tumor mechanism identified
2. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
3. Meat Might Be Behind Many Unidentified Allergic Reactions
4. Predisposing factors for conversion of mild cognitive impairment to AD identified
5. Salmonella Tennessee Identified in a Processed Food Ingredient
6. Gene Mutations Identified for Charcot-Marie-Tooth Syndrome
7. Newly identified proteins critical to FA pathway DNA repair function
8. New Alzheimers Gene Identified
9. Strange Artifact Identified as Ancient Anti-Snoring Device
10. New Alzheimers Risk Genes Identified
11. Mechanism that may trigger degenerative disease identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... Mediaplanet ... awareness for organ transplantation while encouraging readers to sign up as an organ donor ... lifesaving organ transplant. , An organ donor can save up to 8 saves ...
(Date:12/8/2016)... Charleston, WV (PRWEB) , ... December 08, 2016 ... ... that it will become Quality Insights beginning January 1, 2017. The name ... emphasizes its commitment to measuring and improving health care quality. , “We are ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... County, a Property owned by an affiliate of Seavest, has won a prestigious ... Medicine Southern Chester County ambulatory care center (ACC) was named “Best New Development, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Premier Fitness Camp ... FIT , the ultimate weight loss and wellness program, at their world headquarters of ... to provide immediate and long-term results to anyone seeking weight loss, personal development, a ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that due ... Texas, they are expanding their presence in Dallas. One of the most exciting parts ... new jobs to the Dallas and Forth Worth market. STAT takes pride in treating ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec. 9, 2016  Axovant Sciences Ltd. (NYSE: ... company focused on the treatment of dementia, today ... a Phase 2b trial evaluating treatment with intepirdine ... with donepezil plus placebo in people with mild-to-moderate ... of intepirdine to treatment was associated with reduced ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... Patient warming and ... blood during surgeries, lowering the risks of neurological disorders post ... SSIs. The patient warming systems can be segmented into convective ... in turn reduce the stay at hospitals thus, lowering the ...
(Date:12/8/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized by the ... National Standard. To learn more about Diplomat,s career opportunities, ... ... ... WorkplaceDynamics, LLC, a research firm specializing in organizational health and workplace ...
Breaking Medicine Technology: